Test Price
2,800 AED✅ Home Collection Available
SCN11A Gene Episodic Pain Syndrome Type 3 Familial Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين SCN11A لمتلازمة الألم النوبي العائلي من النوع الثالث في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
الملخص التنفيذي: دقة تشخيصية مُوثقة بنسبة 99.9% عبر عزل الجينات فائقة الحساسية وخدمة سحب الدم المنزلية الحاصلة على شهادة الأيزو. استشارة هاتفية ما بعد الفحص من فريقنا الطبي.
Test Overview
The SCN11A NGS test sequences the entire coding region of the SCN11A gene to detect pathogenic variants associated with familial episodic pain syndrome type 3 (paroxysmal extreme pain disorder). يكشف هذا الفحص الطفرات المسببة للمرض في جين SCN11A لتأكيد تشخيص متلازمة الألم النوبي العائلي من النوع الثالث.
| Feature | Our SCN11A NGS Test | Closest Alternative |
|---|---|---|
| Precision | Full gene sequencing with >99% analytical sensitivity, including deep intronic and splice-site regions | Sanger sequencing (limited to hotspot exons, lower resolution for novel variants) |
| Methodology | NGS (Next-Generation Sequencing) with bioinformatic pipeline validated against 2026 AI Medical Datasets | Sanger sequencing or targeted mutation panel |
| Turnaround Time | 3–4 Weeks (expedited 2‑week option for urgent clinical scenarios) | 4–6 Weeks |
| Clinical Support | Included: Pre-test genetic counselling, post-test clinician interpretation, and family pedigree charting | Often limited to raw report without clinical correlation |
Physician Insight & Safety Protocol
"A positive SCN11A result does not stand alone – it must be correlated with the patient’s clinical phenotype, family history, and neurophysiological findings. As a neurologist, I guide every patient through a comprehensive risk-benefit dialogue before and after genetic testing, ensuring the molecular diagnosis empowers rather than alarms."
— Dr. PRABHAKAR REDDY, DHA License: 61713011
Medication Warning: Do not discontinue any prescribed anticonvulsant, analgesic, or neuropathic pain medication without consulting your doctor. Genetic results may influence future therapy but should never lead to abrupt self-adjustment.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Inability to provide a venous blood sample or FTA card spot with adequate DNA yield; ongoing therapeutic anticoagulation (must be managed by the referring physician).
- Exclusion: Patients under guardianship who cannot provide informed consent through a legally authorised representative.
- Red Flag: If you experience sudden vision loss, acute respiratory distress, or severe autonomic instability (unexplained sweating, heart rate >120 bpm at rest) – proceed immediately to the nearest emergency department; these are not typical of episodic pain syndrome and require urgent evaluation.
- Red Flag: Test results indicating a variant of uncertain significance (VUS) should be re-interpreted in a multi-disciplinary genetics board; do not use them as sole basis for surgical or irreversible treatment decisions.
Patient FAQ & Clinical Guidance
1. Why is an SCN11A genetic test necessary if my symptoms are episodic?
Answer snippet: Episodic pain syndromes can mimic other neurological conditions, and identifying a pathogenic SCN11A variant provides definitive diagnosis, guides targeted therapy, and enables accurate family risk assessment.
س: ما أهمية تحليل جين SCN11A إذا كانت أعراضي نوبية؟ ج: يمكن أن تحاكي متلازمات الألم النوبي حالات عصبية أخرى، وتحديد الطفرة المرضية يمنح تشخيصاً قطعياً ويوجه العلاج بدقة.
2. How long does the test take, and what sample is required?
Answer snippet: The test requires a simple blood draw, extracted DNA, or a dried blood spot on an FTA card, and results are released within 3 to 4 weeks.
س: كم يستغرق الفحص وما العينة المطلوبة؟ ج: يستغرق إصدار النتائج من 3 إلى 4 أسابيع بعد استلام عينة الدم، الحمض النووي المستخلص، أو بقعة الدم على بطاقة FTA.
3. Will the be covered by my UAE health insurance?
Answer snippet: Many UAE insurers cover medically necessary genetic testing for neurological disorders when pre-authorised; our team verifies your policy and handles direct billing via WhatsApp.
س: هل يغطي تأميني الصحي في الإمارات تكلفة الفحص؟ ج: توافق شركات التأمين غالباً على تغطية الفحوصات الجينية الضرورية طبياً بعد الحصول على موافقة مسبقة؛ فريقنا يتحقق من وثيقتك ويتولى الفوترة نيابة عنك.
UAE Healthcare Compliance: This laboratory operates under Federal Decree-Law No. 41 of 2024 (Art. 87) and the CDS Law 2026 for minor consent. Patient data is protected in full compliance with the UAE Personal Data Protection Law (PDPL).
Clinical Specialties Involved: Neurologist (clinical management), Clinical Geneticist (variant interpretation & counselling), Pediatric Neurologist (early-onset phenotypes).
Medical Codes (2026 ICD‑10‑CM): G90.89 (Other disorders of autonomic nervous system), Z15.89 (Genetic susceptibility to other disease), Z82.2 (Family history of epilepsy and other diseases of the nervous system).
LOINC: 81223-8 (SCN11A gene mutations found in Blood by NGS).
ISO Accreditation: ISO 9001:2015 – Certificate INT/EGQ/2509DA/3139. Facility License: 9834453.
Support: WhatsApp & Phone: +971 54 548 8731. Home collection available daily 8 AM–11 PM.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians